PURPOSE: To investigate the incidence and clinical relevance of classic and new prognostic markers, IGHV gene mutational status, and chromosomal abnormalities in clinical monoclonal B lymphocytosis (cMBL) compared with Rai stage 0 chronic lymphocytic leukemia (Rai0-CLL). EXPERIMENTAL DESIGN: A group of 136 patients with cMBL and a group of 216 Rai0-CLL cases were investigated prospectively. RESULTS: IGHV-mutated cases were significantly more frequent among cMBLs (P = 0.005), whereas the distribution of CD38 and ZAP-70 positive cases, of patients with NOTCH1 and SF3B1 mutations or exhibiting the major CLL cytogenetic abnormalities, was similar in the two groups. Moreover, no significant differences were found either in IGHV/IGHD/IGHJ gene usage or in the overall prevalence of stereotyped IGHV gene sequences. Cells from cMBL and Rai0-CLL exhibited similar gene and microRNA (miRNA) signatures; in addition, when grouped according to the IGHV mutational status, IGHV-unmutated cases showed different transcriptional signatures compared with IGHV-mutated patients, irrespective of the cMBL or Rai0-CLL classification. cMBL diagnosis per se was predictive of longer progression-free survival. CONCLUSIONS: Our study based on a prospective series of patients indicates that no major differences exist between the circulating cells from cMBL and Rai0-CLL, at least based on a comparison of the markers used in the study. This possibly suggests that the two conditions mainly differ in the initial size of the monoclonal cell population, which may influence the subsequent timing of clonal expansion and clinical manifestations.
PURPOSE: To investigate the incidence and clinical relevance of classic and new prognostic markers, IGHV gene mutational status, and chromosomal abnormalities in clinical monoclonal B lymphocytosis (cMBL) compared with Rai stage 0 chronic lymphocytic leukemia (Rai0-CLL). EXPERIMENTAL DESIGN: A group of 136 patients with cMBL and a group of 216 Rai0-CLL cases were investigated prospectively. RESULTS:IGHV-mutated cases were significantly more frequent among cMBLs (P = 0.005), whereas the distribution of CD38 and ZAP-70 positive cases, of patients with NOTCH1 and SF3B1 mutations or exhibiting the major CLL cytogenetic abnormalities, was similar in the two groups. Moreover, no significant differences were found either in IGHV/IGHD/IGHJ gene usage or in the overall prevalence of stereotyped IGHV gene sequences. Cells from cMBL and Rai0-CLL exhibited similar gene and microRNA (miRNA) signatures; in addition, when grouped according to the IGHV mutational status, IGHV-unmutated cases showed different transcriptional signatures compared with IGHV-mutated patients, irrespective of the cMBL or Rai0-CLL classification. cMBL diagnosis per se was predictive of longer progression-free survival. CONCLUSIONS: Our study based on a prospective series of patients indicates that no major differences exist between the circulating cells from cMBL and Rai0-CLL, at least based on a comparison of the markers used in the study. This possibly suggests that the two conditions mainly differ in the initial size of the monoclonal cell population, which may influence the subsequent timing of clonal expansion and clinical manifestations.
Authors: Brian A McCarthy; Sophia Yancopoulos; Mike Tipping; Xiao-Jie Yan; Xue Ping Wang; Fiona Bennett; Wentian Li; Martin Lesser; Santanu Paul; Erin Boyle; Carolina Moreno; Rosa Catera; Bradley T Messmer; Giovanna Cutrona; Manlio Ferrarini; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Andrew C Rawstron; Nicholas Chiorazzi Journal: Immunol Res Date: 2015-12 Impact factor: 2.829
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: F Arruga; B Gizdic; C Bologna; S Cignetto; R Buonincontri; S Serra; T Vaisitti; K Gizzi; N Vitale; G Garaffo; E Mereu; F Diop; F Neri; D Incarnato; M Coscia; J Allan; R Piva; S Oliviero; R R Furman; D Rossi; G Gaidano; S Deaglio Journal: Leukemia Date: 2016-12-26 Impact factor: 11.528
Authors: G Cutrona; S Matis; M Colombo; C Massucco; G Baio; F Valdora; L Emionite; S Fabris; A G Recchia; M Gentile; C E Neumaier; D Reverberi; R Massara; S Boccardo; L Basso; S Salvi; F Rosa; M Cilli; S Zupo; M Truini; P Tassone; M Calabrese; M Negrini; A Neri; F Morabito; F Fais; M Ferrarini Journal: Leukemia Date: 2017-01-05 Impact factor: 11.528